Telix Pharmaceuticals
Latest round
- Seed
Last raised
- Jun 2016
Total raised
- $8.5M
Investors
- 5
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, founded in 2015 in Melbourne, Australia, is focused on the development of innovative radiopharmaceuticals for oncology. The CEO, David Cade, has a history of leadership in biopharmaceutical companies, providing a foundation for Telix's growth.Telix Pharmaceuticals focuses on the development and commercialization of theranostic radiopharmaceuticals, combining therapeutic and diagnostic functions to address significant unmet medical needs in oncology.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) for detecting prostate cancer, and Gozellix®, another product currently under development. These agents utilize targeted radiation to enhance treatment decision-making and deliver personalized therapies, particularly in areas of urologic oncology, neuro-oncology, musculoskeletal oncology, and bone marrow conditioning. Telix’s products are primarily marketed in North America, including the United States and Canada, as well as other global markets where regulatory approvals have been attained.Telix Pharmaceuticals reports significant revenues from its product offerings, primarily generated through direct sales to healthcare providers and institutions utilizing the company's imaging agents in clinical settings. Transactions typically occur via contracts with hospitals and clinics, where products such as Illuccix® are purchased for use in diagnostic imaging processes. The firm operates on a business-to-business (B2B) model, focusing on institutional partnerships that facilitate the distribution of its products.Telix Pharmaceuticals plans to utilize the proceeds from its AUD 50 million IPO in November 2017 to fund the development and completion of clinical trials for its pipeline in renal, prostate, and brain cancer (glioblastoma), as well as to complete multiple clinical and product development milestones over the next 24 months. The company aims to launch new products in its pipeline and expand into additional markets, specifically targeting regions in Europe and Asia by 2024. These initiatives are expected to enhance the company's offerings and strengthen its market presence.
Who invested in Telix Pharmaceuticals
5 investors across 1 round
See all investors in Telix Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jun 1, 2016
Amount
$8.5M
Investors
Questions about Telix Pharmaceuticals
Who invested in Telix Pharmaceuticals?
Telix Pharmaceuticals has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Telix Pharmaceuticals raised?
Telix Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Telix Pharmaceuticals last raise money?
Telix Pharmaceuticals's most recent round on record is a Seed, in Jun 2016.
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals Limited, founded in 2015 in Melbourne, Australia, is focused on the development of innovative radiopharmaceuticals for oncology.
Where is Telix Pharmaceuticals headquartered?
Telix Pharmaceuticals is headquartered in Melbourne, Australia.
Which VCs invest in companies like Telix Pharmaceuticals?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back biotechnology companies at Telix Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Telix Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.